Literature DB >> 19258523

Kaposi's sarcoma-associated herpesvirus-G protein-coupled receptor-expressing endothelial cells exhibit reduced migration and stimulated chemotaxis by chemokine inverse agonists.

Jean-Pierre Couty1, Monica Lupu-Meiri, Yoram Oron, Marvin C Gershengorn.   

Abstract

A constitutively active G protein-coupled receptor (GPCR) encoded by Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) (KSHV) is expressed in endothelial (spindle) cells of Kaposi's sarcoma lesions. In this study, we report novel effects of basal signaling by this receptor and of inverse agonist chemokines on migration of KSHV-GPCR-expressing mouse lung endothelial cells. We show that basal signaling by KSHV-GPCR inhibits migration of endothelial cells in two systems, movement through porous filters and in vitro wound closure. Naturally occurring chemokines, interferon gamma-inducible protein-10 and stromal-derived factor-1, which act as inverse agonists at KSHV-GPCR, abrogate the inhibition of migration and stimulate directed migration (or chemotaxis) of these cells. Thus, the expression of KSHV-GPCR may allow infected endothelial cells in situ to remain in a localized environment or to directionally migrate along a gradient of specific chemokines that are inverse agonists at KSHV-GPCR.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19258523      PMCID: PMC2683784          DOI: 10.1124/jpet.108.147686

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  33 in total

Review 1.  The molecular genetics of chemotaxis: sensing and responding to chemoattractant gradients.

Authors:  R A Firtel; C Y Chung
Journal:  Bioessays       Date:  2000-07       Impact factor: 4.345

2.  Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor signals through multiple pathways in endothelial cells.

Authors:  J P Couty; E Geras-Raaka; B B Weksler; M C Gershengorn
Journal:  J Biol Chem       Date:  2001-07-11       Impact factor: 5.157

3.  Transcription program of human herpesvirus 8 (kaposi's sarcoma-associated herpesvirus).

Authors:  M Paulose-Murphy; N K Ha; C Xiang; Y Chen; L Gillim; R Yarchoan; P Meltzer; M Bittner; J Trent; S Zeichner
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

4.  Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor constitutively activates NF-kappa B and induces proinflammatory cytokine and chemokine production via a C-terminal signaling determinant.

Authors:  M Schwarz; P M Murphy
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

5.  The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration.

Authors:  D N Streblow; C Soderberg-Naucler; J Vieira; P Smith; E Wakabayashi; F Ruchti; K Mattison; Y Altschuler; J A Nelson
Journal:  Cell       Date:  1999-11-24       Impact factor: 41.582

6.  Constitutive activation of NF-kappa B and secretion of interleukin-8 induced by the G protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus involve G alpha(13) and RhoA.

Authors:  L W Shepard; M Yang; P Xie; D D Browning; T Voyno-Yasenetskaya; T Kozasa; R D Ye
Journal:  J Biol Chem       Date:  2001-10-04       Impact factor: 5.157

7.  The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha.

Authors:  A Sodhi; S Montaner; V Patel; M Zohar; C Bais; E A Mesri; J S Gutkind
Journal:  Cancer Res       Date:  2000-09-01       Impact factor: 12.701

8.  Activation of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi's sarcoma pathogenesis.

Authors:  S Pati; M Cavrois; H G Guo; J S Foulke; J Kim; R A Feldman; M Reitz
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

9.  The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B.

Authors:  S Montaner; A Sodhi; S Pece; E A Mesri; J S Gutkind
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

10.  Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma.

Authors:  T Y Yang; S C Chen; M W Leach; D Manfra; B Homey; M Wiekowski; L Sullivan; C H Jenh; S K Narula; S W Chensue; S A Lira
Journal:  J Exp Med       Date:  2000-02-07       Impact factor: 14.307

View more
  7 in total

Review 1.  Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis.

Authors:  Qiliang Cai; Suhbash C Verma; Jie Lu; Erle S Robertson
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

2.  Kaposi's sarcoma-associated herpesvirus downregulates transforming growth factor β2 to promote enhanced stability of capillary-like tube formation.

Authors:  Terri A DiMaio; Kimberley D Gutierrez; Michael Lagunoff
Journal:  J Virol       Date:  2014-10-01       Impact factor: 5.103

3.  A multiplex panel of plasma markers of immunity and inflammation in classical kaposi sarcoma.

Authors:  Peter V Aka; Troy J Kemp; Charles S Rabkin; Meredith S Shiels; Mark N Polizzotto; Carmela Lauria; Francesco Vitale; Ligia A Pinto; James J Goedert
Journal:  J Infect Dis       Date:  2014-08-22       Impact factor: 5.226

4.  A knockout mutation of a constitutive GPCR in Tetrahymena decreases both G-protein activity and chemoattraction.

Authors:  Thomas J Lampert; Kevin D Coleman; Todd M Hennessey
Journal:  PLoS One       Date:  2011-11-29       Impact factor: 3.240

5.  Latent KSHV infection of endothelial cells induces integrin beta3 to activate angiogenic phenotypes.

Authors:  Terri A DiMaio; Kimberley D Gutierrez; Michael Lagunoff
Journal:  PLoS Pathog       Date:  2011-12-08       Impact factor: 6.823

6.  KSHV Induction of Angiogenic and Lymphangiogenic Phenotypes.

Authors:  Terri A Dimaio; Michael Lagunoff
Journal:  Front Microbiol       Date:  2012-03-30       Impact factor: 5.640

Review 7.  Cytokine-Targeted Therapeutics for KSHV-Associated Disease.

Authors:  Nedaa Alomari; Jennifer Totonchy
Journal:  Viruses       Date:  2020-09-28       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.